Iovance Biotherapeutics (NASDAQ:IOVA) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Posted by Geri Gentry on Aug 8th, 2026

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02, Briefing.com reports. Iovance Biotherapeutics had a negative return on equity of 40.92% and a negative net margin of 89.11%.The firm had revenue of $198.63 million during the quarter, compared to the consensus estimate of $87.83 million. During the same period in the prior year, the company earned ($0.33) EPS. The firm’s revenue was up 65.7% compared to the same quarter last year.

Here are the key takeaways from Iovance Biotherapeutics’ conference call:

Record second-quarter performance: Revenue reached $99.3 million, up 66% year over year and 39% sequentially, led by approximately $91 million in Amtagvi sales that exceeded guidance. Gross margin rose to a record 56% as manufacturing volume and in-house efficiencies improved.
Commercial adoption continues to broaden. Iovance reported more than 95 Authorized Treatment Centers, including a growing community-based presence, and expects at least 110 centers by year-end; management said demand remained strong entering the third quarter.
Pipeline milestones advanced: Enrollment is nearly complete in the pivotal lung cancer trial, with an update expected in the fourth quarter and a potential supplemental filing targeted for 2027. Lifileucel also received FDA Fast Track designation in two soft-tissue sarcoma indications, while early endometrial and serous cancer data supported a protocol amendment aimed at an expedited approval pathway.
Financial flexibility improved. Cash, cash equivalents, and short-term investments totaled approximately $304 million at June 30, which management expects to fund operations into the second half of 2028; research and development expenses declined for the fourth consecutive quarter.
The company is reviewing its 2026 total revenue guidance of $350 million to $370 million and expects to issue an update during the third quarter. Management characterized the revision as driven by improved visibility into demand, but the updated outlook and timing remain unspecified.

Iovance Biotherapeutics Price Performance

Iovance Biotherapeutics stock traded up $0.13 during trading on Friday, reaching $6.34. 30,912,913 shares of the company were exchanged, compared to its average volume of 19,318,560. The stock’s 50 day simple moving average is $4.40 and its two-hundred day simple moving average is $3.80. The company has a market capitalization of $2.83 billion, a P/E ratio of -8.68 and a beta of 0.71. Iovance Biotherapeutics has a 52-week low of $1.76 and a 52-week high of $6.92.

Institutional Trading of Iovance Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Motley Fool Asset Management LLC purchased a new position in shares of Iovance Biotherapeutics during the 4th quarter worth $29,000. Granite Investment Partners LLC purchased a new stake in shares of Iovance Biotherapeutics in the fourth quarter valued at about $29,000. Diversify Wealth Management LLC purchased a new stake in shares of Iovance Biotherapeutics in the second quarter valued at about $34,000. Dynamic Technology Lab Private Ltd acquired a new stake in Iovance Biotherapeutics during the fourth quarter worth about $46,000. Finally, HighTower Advisors LLC increased its position in Iovance Biotherapeutics by 67.9% during the fourth quarter. HighTower Advisors LLC now owns 19,089 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 7,718 shares during the last quarter. 77.03% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

Positive Sentiment: Record revenue and strong Amtagvi demand: Second-quarter revenue reached approximately $99.3 million, up 66% year over year and well above analyst expectations. U.S. Amtagvi revenue was about $91 million, rising 40% from the fourth quarter, helping drive the earnings beat. Iovance Q2 2026 results
Positive Sentiment: Loss narrowed and margins improved: Iovance reported a loss of $0.11 per share, better than the $0.13–$0.17 consensus range and an improvement from $0.33 per share a year earlier. Gross margin increased to 56% as manufacturing and cost efficiencies improved. Zacks Q2 earnings report
Positive Sentiment: Analyst support strengthened: Citizens JMP raised its IOVA price target from $5 to $8 and assigned a “market outperform” rating, reinforcing bullish sentiment following the results. Benzinga analyst update
Positive Sentiment: Pipeline catalysts expanded: The FDA granted Fast Track Designation to lifileucel for soft tissue sarcomas. Investors are also focused on upcoming data from melanoma and non-small-cell lung cancer programs, with additional trial updates expected later this year. Iovance pipeline update
Neutral Sentiment: Management is reviewing its 2026 revenue outlook of $350 million to $370 million because of stronger demand, but plans to provide an updated forecast in the third quarter. The company ended June with approximately $304 million in cash, expected to fund operations into the second half of 2028.
Negative Sentiment: Iovance remains unprofitable, posting a quarterly net loss of approximately $47.3 million, while research and development expenses totaled $58.9 million. Continued losses and execution risks around commercialization and clinical trials remain important risks for investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on IOVA shares. Robert W. Baird set a $6.00 target price on shares of Iovance Biotherapeutics in a research note on Friday. Chardan Capital reduced their target price on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Citigroup reissued an “outperform” rating on shares of Iovance Biotherapeutics in a research note on Friday. Barclays boosted their price target on shares of Iovance Biotherapeutics from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Thursday, July 2nd. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.00.

Check Out Our Latest Stock Report on Iovance Biotherapeutics

About Iovance Biotherapeutics

(Get Free Report)

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.